Answers are grounded in this paper and cite their sources.
BACKGROUND: Antimalarial drug resistance remains a significant challenge in the fight against malaria in Cameroon. Given the high prevalence of malaria in Makenene in central Cameroon and the limited knowledge of drug resistance profiles in the area, the prevalence of Plasmodium falciparum drug resistance genetic markers was assessed. METHODS: 185 samples from asymptomatic individuals with P. falciparum parasitaemia collected between September and October 2021 were sequenced for the Pfdhfr, Pfdhps, Pfcrt, Pfmdr1, and PfK13 genes. RESULTS: haplotype, selected in parasites with recrudescence in patient treated with dihydroartemisinin-piperaquine. Moreover, no mutation associated with artemisinin partial resistance was detected in PfK13. CONCLUSIONS: The in-depth analysis of genetic mutations associated with antimalarials resistance in this study, notably those with a high prevalence of mutations on the Pfdhfr and Pfdhps genes, highlights the immediate need for proactive strategies to combat resistance in Makenene. Continuous monitoring, including molecular and in vivo surveillance is crucial to uphold the effectiveness of current treatments and, more particularly, artemisinin-based combination therapies, and to enable better decision-making on effective treatment policy in Cameroon and in Africa as a whole.
No takes yet. Share an insight, caveat, or question.
Kala-Chouakeu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: